Nucleus RadioPharma

From molecule to market, faster.

Nucleus RadioPharma is an end-to-end CDMO supporting radiopharmaceutical development, manufacturing, and supply from clinical programs through commercial production.

Meet us at SNMMI 2026, Booth 1445. We’ll be showcasing our new direct-from-vial infusion system and look forward to seeing you there.

Radiopharmaceutical programs require coordinated development, manufacturing, and supply chain infrastructure to support clinical and commercial execution.

We build the infrastructure required for scale.

A CDMO focused solely on your program

We do not compete with our clients—we partner with them to ensure life-changing radiopharmaceutical therapies reach patients efficiently and cost-effectively.

Isotope-Flexible Manufacturing

Supporting Ac-225, Lu-177, Pb-212, Cu-67, I-131 and beyond.

Rochester, MN Facility Alongside Mayo Clinic

Purpose-built to support your program at every stage—preclinical, clinical, and commercial.

End-to-End Supply Chain & Distribution

White-label solutions, supply chain expertise, and regulatory compliance.

Strategic Industry Partnerships

Working with Artbio and Clarity to bring new radiotherapies to market.

Supporting radiopharmaceutical programs at every stage

Robust manufacturing infrastructure

We focus exclusively on manufacturing and supply chain—not isotope production—so you can bring your radiopharmaceuticals to patients faster.

  • Clinical & commercial manufacturing
  • Regulatory & compliance expertise
  • White-label packaging & distribution

Flexible by design

Our facilities are designed from the ground up to support any formula, any process, any isotope without the limitations of legacy infrastructure.

  • Customizable manufacturing
  • Faster R&D to production transition
  • Reliable, rapid delivery

Not every CDMO has the scientific expertise and network needed to develop, manufacture, and deliver your radiotherapeutics.

We do.

Nucleus RadioPharma thrives from a fresh start, free from legacy constraints. This, combined with an experienced team and open communication, fuels the innovative thinking needed to scale and launch groundbreaking radiopharmaceuticals.”

– Conrad Wüller ARTBIO

MEET US AT SNMMI 2026

Society of Nuclear Medicine and Molecular Imaging Annual Meeting

Booth # 1445
May 30–June 2, 2026 • Los Angeles, California